News

No link between head and neck cancers and marijuana use


 

FROM ARCHIVES OF ORAL BIOLOGY

References

Marijuana use does not seem to be a risk factor for head and neck cancer (HNC) suggests a meta-analysis including nine case-control studies.

Smithore

The chance of developing head and neck cancer in individuals who had smoked marijuana in their lifetime was estimated using an odds ratio, and controlling for age, sex, race, and tobacco consumption.

Approximately 12.6% of the patients who developed HNC and 14.3% of the controls were marijuana users. No association was found between exposure to marijuana and HNC (odds ratio = 1.021).

“Despite several inferences that have made to date, there is currently insufficient epidemiological evidence to support a positive or negative association in marijuana use and the development of HNC,” the researchers said.

Future studies on the long-term effects of marijuana use and “the mechanism of action of cannabinoids in specific tissues in animal models and humans” are needed, according to the researchers.

Read the full study in Archives of Oral Biology (doi: 10.1016/j.archoralbi.2015.09.009).

klennon@frontlinemedcom.com

Recommended Reading

Moderate THST was most effective at treating thyroid cancer
MDedge Hematology and Oncology
ASCO 2015: from data and learning, to daily practice
MDedge Hematology and Oncology
A weekly speech and language therapy service for head and neck radiotherapy patients during treatment: maximizing accessibility and efficiency
MDedge Hematology and Oncology
Harnessing new data on immunotherapies
MDedge Hematology and Oncology
Similar outcomes for salvage vs. planned surgery after chemoradiotherapy in esophageal cancer
MDedge Hematology and Oncology
Persistent HPV16 DNA in oral rinse signaled oropharyngeal cancer’s return
MDedge Hematology and Oncology
ESTIMABL trial: Current rhTSH cost outweighs benefits
MDedge Hematology and Oncology
JCO publishes special issue on head and neck cancers
MDedge Hematology and Oncology
Radiation field optimization may preserve salivary gland function
MDedge Hematology and Oncology
ECC: Pembrolizumab hits mark in heavily pretreated nasopharngeal cancer
MDedge Hematology and Oncology